Physician profile
Kelly Lawrence
NPI 1902066996
$4,555.63
in general payments reported to CMS, 2019-2025
17 companies · $2,818 in 2025
The $2,818 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $291 · 2024: $1,447 · 2025: $2,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,555.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $670.60 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $541.54 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $530.80 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $478.87 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $408.63 | 2023-2025 | Caplyta |
| Abbvie INC. | $359.68 | 2024-2025 | |
| Lundbeck LLC | $355.00 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $298.80 | 2024-2025 | Cobenfy, Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $221.84 | 2024-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $210.31 | 2024-2025 | Invega Sustenna |
| Collegium Pharmaceutical, INC. | $171.39 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $149.02 | 2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $59.89 | 2024 | |
| Alkermes, INC. | $36.06 | 2025 | Vivitrol |
| Genzyme Corporation | $31.65 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $15.90 | 2025 | Zepbound |
| Supernus Pharmaceuticals, INC. | $15.65 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.